ArticleFrontiers in endocrinology2025
Association between central thyroid hormone sensitivity and prediabetes: Tehran thyroid study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thyroid Hormones and Metabolic Syndrome: A Narrative Review of Findings from 18 Years of Follow-up in Tehran Thyroid Study (TTS).International journal of endocrinology and metabolism · 2026Review
- Thyroid Hormones and Type 2 Diabetes Mellitus: A Narrative Review of Findings From 18 Years of Follow-up in the Tehran Thyroid Study.International journal of endocrinology and metabolism · 2026Review
- A novel marker for predicting malignancy in patients with thyroid nodules diagnosed as AUS on initial cytology: thyroid hormone sensitivity.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid hormone sensitivity indices represent a recently proposed clinical entity related to metabolic health outcomes. The link between thyroid hormone sensitivity and prediabetes is not clear. This population-based study investigated the association between thyroid hormone sensitivity indices and prediabetes. Methods: Among 5,783 participants over 20 years, after excluding those receiving thyroid medications or corticosteroid drugs, having thyroid surgery, having a history of cancer, pregnant women, and those with end-stage renal disease, 4,356 subjects were included in the study. The odds ratio (OR) and 95% confidence interval (95%CI) for prediabetes in the general and euthyroid population per 1-SD increase in thyroid hormone resistance indices (PFTQI, TSHI, and lnTT4RI) were reported with logistic regression models. Results: One SD increase in PTFQI was significantly associated with lower odds of prediabetes even after total adjustment (OR:0.88; 95%CI: 0.82-0.94). The association was observed in women, non-smokers, and those with negative anti-thyroid peroxidase antibodies. In the euthyroid subgroup, one SD increase in PTFQI, TSHI, and lnTT4RI showed lower odds of prediabetes and [PTFQI: 0.89 (95%CI: 0.83-0.97); TSHI: 0.83 (95%CI: 0.74-0.94); lnTT4RI: 0.83 (95%CI: 0.74-0.93)]. We also found a negative correlation between thyroid hormone sensitivity indices and fasting plasma glucose (PTFQI: r =-0.094, TSHI:-0.1, and lnTT4RI: r =-0.098) and 2-h post-challenge glucose (PTFQI: r =-0.096, TSHI:-0.054, and lnTT4RI: r =-0.031). Conclusion: Lower central sensitivity to thyroid hormone, as represented by increased TSHI, TT4RI, and PTFQI, is associated with a lower risk of prediabetes, even in euthyroid individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.